Structures of TorsinA and its disease-mutant complexed with an activator reveal the molecular basis for primary dystonia

  1. F Esra Demircioglu
  2. Brian A Sosa
  3. Jessica Ingram
  4. Hidde L Ploegh
  5. Thomas U Schwartz  Is a corresponding author
  1. Massachusetts Institute of Technology, United States
  2. Whitehead Institute for Biomedical Research, United States

Abstract

The most common cause of early onset primary dystonia, a neuromuscular disease, is a glutamate deletion (ΔE) at position 302/303 of TorsinA, a AAA+ ATPase that resides in the endoplasmic reticulum. While the function of TorsinA remains elusive, the ΔE mutation is known to diminish binding of two TorsinA ATPase activators: lamina-associated protein 1 (LAP1) and its paralog, luminal domain like LAP1 (LULL1). Using a nanobody as a crystallization chaperone, we obtained a 1.4 Å crystal structure of human TorsinA in complex with LULL1. This nanobody likewise stabilized the weakened TorsinAE-LULL1 interaction, which enabled us to solve its structure at 1.4 Å also. A comparison of these structures shows, in atomic detail, the subtle differences in activator interactions that separate the healthy from the diseased state. This information may provide a structural platform for drug development, as a small molecule that rescues TorsinAΔE could serve as a cure for primary dystonia.

Article and author information

Author details

  1. F Esra Demircioglu

    Department of Biology, Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    F Esra Demircioglu, Filed a provisional patent application protecting the use of the crystal structures (U.S.P.T.O. No. 62/330,683).
  2. Brian A Sosa

    Department of Biology, Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    Brian A Sosa, Filed a provisional patent application protecting the use of the crystal structures (U.S.P.T.O. No. 62/330,683).
  3. Jessica Ingram

    Whitehead Institute for Biomedical Research, Cambridge, United States
    Competing interests
    No competing interests declared.
  4. Hidde L Ploegh

    Whitehead Institute for Biomedical Research, Cambridge, United States
    Competing interests
    No competing interests declared.
  5. Thomas U Schwartz

    Department of Biology, Massachusetts Institute of Technology, Cambridge, United States
    For correspondence
    tus@mit.edu
    Competing interests
    Thomas U Schwartz, Filed a provisional patent application protecting the use of the crystal structures (U.S.P.T.O. No. 62/330,683).
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8012-1512

Funding

Dystonia Medical Research Foundation

  • Thomas U Schwartz

National Institutes of Health

  • Thomas U Schwartz

National Institutes of Health

  • Hidde L Ploegh

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2016, Demircioglu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,181
    views
  • 616
    downloads
  • 55
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. F Esra Demircioglu
  2. Brian A Sosa
  3. Jessica Ingram
  4. Hidde L Ploegh
  5. Thomas U Schwartz
(2016)
Structures of TorsinA and its disease-mutant complexed with an activator reveal the molecular basis for primary dystonia
eLife 5:e17983.
https://doi.org/10.7554/eLife.17983

Share this article

https://doi.org/10.7554/eLife.17983

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Jie Luo, Jeff Ranish
    Tools and Resources

    Dynamic conformational and structural changes in proteins and protein complexes play a central and ubiquitous role in the regulation of protein function, yet it is very challenging to study these changes, especially for large protein complexes, under physiological conditions. Here, we introduce a novel isobaric crosslinker, Qlinker, for studying conformational and structural changes in proteins and protein complexes using quantitative crosslinking mass spectrometry. Qlinkers are small and simple, amine-reactive molecules with an optimal extended distance of ~10 Å, which use MS2 reporter ions for relative quantification of Qlinker-modified peptides derived from different samples. We synthesized the 2-plex Q2linker and showed that the Q2linker can provide quantitative crosslinking data that pinpoints key conformational and structural changes in biosensors, binary and ternary complexes composed of the general transcription factors TBP, TFIIA, and TFIIB, and RNA polymerase II complexes.

    1. Structural Biology and Molecular Biophysics
    Yuanyuan Wang, Fan Xu ... Yongning He
    Research Article

    SCARF1 (scavenger receptor class F member 1, SREC-1 or SR-F1) is a type I transmembrane protein that recognizes multiple endogenous and exogenous ligands such as modified low-density lipoproteins (LDLs) and is important for maintaining homeostasis and immunity. But the structural information and the mechanisms of ligand recognition of SCARF1 are largely unavailable. Here, we solve the crystal structures of the N-terminal fragments of human SCARF1, which show that SCARF1 forms homodimers and its epidermal growth factor (EGF)-like domains adopt a long-curved conformation. Then, we examine the interactions of SCARF1 with lipoproteins and are able to identify a region on SCARF1 for recognizing modified LDLs. The mutagenesis data show that the positively charged residues in the region are crucial for the interaction of SCARF1 with modified LDLs, which is confirmed by making chimeric molecules of SCARF1 and SCARF2. In addition, teichoic acids, a cell wall polymer expressed on the surface of gram-positive bacteria, are able to inhibit the interactions of modified LDLs with SCARF1, suggesting the ligand binding sites of SCARF1 might be shared for some of its scavenging targets. Overall, these results provide mechanistic insights into SCARF1 and its interactions with the ligands, which are important for understanding its physiological roles in homeostasis and the related diseases.